AS/Spondyloarthritis

What Worries You, Masters You (7.1.2022)
Save

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com. Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

FDA approved Abbvies risakizumab-rzaa

Read Article

Inferior IL-17 Inhibitor Responses in Psoriatic Women
Save

Jack Cush, MD

Jun 27, 2022

Pooled data from two large ixekizumab (IXE) trials show that male patients had greater clinical responses than did female patients with psoriatic arthritis are largely unexplored. Reasons for this differential treatment responses to an interleukin-17A inhibitor (IXE) between male and female

Read Article

Two Week Methotrexate Hold with COVID-19 Vaccination
Save

Jack Cush, MD

Jun 24, 2022

A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal.

Read Article

#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj

Links:

https://bit.ly/3xBn2D5

Dr. John Cush @RheumNow( View Tweet )

Jun 18, 2022

Two Week Twitter (6.17.2022)
Save

Jack Cush, MD

Jun 17, 2022

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Read Article

Spondyloarthritis and COVID-19
Save

Robert Chao, MD

Jun 15, 2022

There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question.

Read Article

450 axSpA pts followed 2868 Pt-yrs, 48% on TNFis. TNFi Rx pts had reduced CV risk (HR 0.30; 0.10–0.85), but no longer signif after adjustment for CRP, ESR (HR 0.37, 0.12–1.12, p = 0.077). Reduced CV risk, may not be specifically due to TNFi use https://t.co/mVHYn3PteL https://t.co/bgKWreBL8z

Links:

https://bit.ly/3HpeJ1D

Dr. John Cush @RheumNow( View Tweet )

Jun 14, 2022

Watch: The Microbiome in Spondyloarthritis Can microbes trigger SpA/PsA?https://t.co/KN7dMFU9qo https://t.co/k3M5QfwqGp

Links:

https://bit.ly/3MWdDMk

Dr. John Cush @RheumNow( View Tweet )

Jun 14, 2022

EULAR 2022 Top 10 Abstracts (6.10.2022)
Save

Jack Cush, MD

Jun 10, 2022

Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media

Read Article

Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51

Links:

https://bit.ly/3xcrQ1B

Dr. John Cush @RheumNow( View Tweet )

Jun 07, 2022

Time to consider gender stratification in AxSpA diagnosis and management
Save

Aurelie Najm, MD, PhD

Jun 07, 2022

Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked. Two abstracts have shed light on relevant gender-based differences in AxSpA assessment or treatment.

Read Article

Updates on Axial SpA from #EULAR2022 @RheumNow https://t.co/0dGPUpksxT

Links:

Update on Axial SpA at EULAR 2022 | RheumNow

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 05, 2022

Update on Axial SpA at #EULAR2022 This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). Dr Antoni Chan shares his picks of abstracts from the conference.https://t.co/AhUC7ORrZi https://t.co/1olLoNS5Ey

Links:

https://bit.ly/3mln78E

Dr. John Cush @RheumNow( View Tweet )

Jun 05, 2022

Spondyloarthritis and COVID-19 With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022 https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL

Links:

https://bit.ly/3zhduzz

Dr. John Cush @RheumNow( View Tweet )

Jun 05, 2022

Update on Axial SpA at EULAR 2022
Save

Antoni Chan, MD, PhD

Jun 04, 2022

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article

New biomarker for atherosclerosis, cardiovascular risk and disease activity in axSpA? Low Irisin associated with subclinical atherosclerosis, high CV risk and more severe disease activity in axSpA @RheumNow #EULAR2022 ABST#POS0327

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022

Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings. Existing MRI scoring may underserve axSpA in women. Added to therapy differences, a lot to readdress for our female axSpA patients. from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM

David Liew @drdavidliew( View Tweet )

Jun 04, 2022

Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity. So much more to digest.... @RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022

Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022

Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial Primary endpoint (ASAS40) and secondary endpoints met No malignancy, MACE, VTE, death @RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022

Does treating spondyloarthritis early matter? Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA axSpA - no difference in response between early vs. established disease @RheumNow #EULAR2022 ABST#POS0302

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022

What guides treatment decisions in AxSpA? Bolt et al showed patients assessed in clinical remission, 1/3 had BASDAI >3.5. Treatment unchanged as low disease activity, awaiting effects of current Rx, complaints not related to axSpA, patient preference #EULAR2022 @RheumNow POS0303

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 04, 2022

Treatment of active SpA improves depressive symptoms in SpA with HADS-D score reducing. This was greatest for TNFi followed by NSAIDs and csDMARDs. TNFi reduced the proportion of patients (48% to 29%) with depressive symptoms at follow up Webers et al #EULAR2022 @RheumNow POS0304

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 04, 2022

Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 04, 2022

New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bDMARD-IR (ASAS40 45% vs 18% and the onset of effect seen by week 4), no new safety risks identified in the SELECT-AXIS 2 study by Van de Heijde et al #EULAR2022 @RheumNow POS0306 https://t.co/LCQBf38GWe

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 04, 2022

Recent Blogs

Axial Disease in Psoriatic Arthritis
Save

Philip Mease, MD

Apr 19, 2022

Inflammatory involvement of the axial skeleton and sacroiliac joints occurs, on average, in 40-50% of patients with psoriatic arthritis (PsA). When present, axial involvement is a “biomarker” of more severe PsA disease: more severe peripheral joint disease, enthesitis, skin disease, pain, impaired function and quality of life, and work productivity. Thus, it is important to recognize and include in a comprehensive PsA treatment approach. Read Post